Market research
6118.HK Austar Lifesciences Limited
HK HKD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 364M
- P/E ratio
- 8.88
- Analyst target
- Not available
- Dividend yield
- Not available
- Beta
- 0.86
Profile
Company facts
- Exchange
- HK
- Currency
- HKD
- Sector
- Healthcare
- Industry
- Medical Devices
- ISIN
- KYG0632L1023
- Market cap
- 364M
- P/E ratio
- 8.88
- Analyst target
- Not available
- Dividend yield
- Not available
- Beta
- 0.86
About
About Austar Lifesciences Limited
Austar Lifesciences Limited, an investment holding company, provides integrated engineering solutions to pharmaceutical manufacturers and research institutes in Mainland China and internationally. It operates through Integrated Process and Packaging Equipment & Systems (IPS); Consulting, Digitalization and Construction (CDC); and Life Science Equipment and Consumables (SIC) segments. The company also offers clean utility equipment and chemical pharmaceutical preparation systems; bioprocess equipment and systems; clean room, automation control, and monitoring systems; powder and solid equipment and systems; aseptic freeze-drying, filling, and visual inspection solutions; pharmaceutical process contamination control products; packaging and aseptic containment products; biosafety and lab animal equipment and consumables; and laboratory one-stop solutions. In addition, it provides consulting and engineering technical services; compliance and validation services; digital factory services; clean room HVAC/EMS/BMS services; and upgrade, retrofit, and maintenance services. Further, it engages in life science consumables, advanced therapies, and advanced bioprocessing technologies, as well as engineering design services. Austar Lifesciences Limited was founded in 1991 and is headquartered in Shanghai, China.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the 6118.HK discussion.
5 years, 4 months ago
Austar Lifesciences Limited is currently in a long term uptrend where the price is trading 188.1% above its 200 day moving average.
From a valuation standpoint, the stock is 98.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 2.3.
Austar Lifesciences Limited's total revenue sank by 9.3% to $518M since the same quarter in the previous year.
Its net income has increased by 225.9% to $13M since the same quarter in the previous year.
Finally, its free cash flow grew by 43.8% to $18M since the same quarter in the previous year.
Based on the above factors, Austar Lifesciences Limited gets an overall score of 4/5.